Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS)
An Open-Label, Single-Arm Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Patients With Early Stage Relapsing Remitting Multiple Sclerosis
Sponsor: Hoffmann-La Roche
Terminated
The study was terminated earlier as the study sponsor collected sufficient data to perform all analyses as per pre-specified endpoints in the study protocol.
Other terminated trials from Hoffmann-La Roche
Other Multiple Sclerosis, Relapsing-Remitting trials with similar outcome
A PHASE3 clinical study on Multiple Sclerosis, Relapsing-Remitting, this trial is terminated or withdrawn. The trial is conducted by Hoffmann-La Roche and has accumulated 49 data snapshots since 2017. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
49 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE3
-
Feb 2025 — Sep 2025 [monthly]
Terminated PHASE3
Status: Completed → Terminated
-
Sep 2024 — Feb 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Nov 2023 — Jul 2024 [monthly]
Completed PHASE3
▶ Show 44 earlier versions
-
Jun 2023 — Nov 2023 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
May 2023 — Jun 2023 [monthly]
Active Not Recruiting PHASE3
-
Mar 2023 — May 2023 [monthly]
Active Not Recruiting PHASE3
-
Feb 2023 — Mar 2023 [monthly]
Active Not Recruiting PHASE3
-
Jan 2023 — Feb 2023 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Dec 2022 — Jan 2023 [monthly]
Recruiting PHASE3
Status: Active Not Recruiting → Recruiting
-
Nov 2022 — Dec 2022 [monthly]
Active Not Recruiting PHASE3
-
Sep 2022 — Nov 2022 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Jul 2022 — Sep 2022 [monthly]
Recruiting PHASE3
Status: Active Not Recruiting → Recruiting
-
Jun 2022 — Jul 2022 [monthly]
Active Not Recruiting PHASE3
-
Mar 2022 — Jun 2022 [monthly]
Active Not Recruiting PHASE3
-
Feb 2022 — Mar 2022 [monthly]
Active Not Recruiting PHASE3
-
Nov 2021 — Feb 2022 [monthly]
Active Not Recruiting PHASE3
-
Sep 2021 — Nov 2021 [monthly]
Active Not Recruiting PHASE3
-
May 2021 — Sep 2021 [monthly]
Active Not Recruiting PHASE3
-
Jan 2021 — May 2021 [monthly]
Active Not Recruiting PHASE3
-
Dec 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE3
-
Nov 2020 — Dec 2020 [monthly]
Active Not Recruiting PHASE3
-
Sep 2020 — Nov 2020 [monthly]
Active Not Recruiting PHASE3
-
Jun 2020 — Sep 2020 [monthly]
Active Not Recruiting PHASE3
-
May 2020 — Jun 2020 [monthly]
Active Not Recruiting PHASE3
-
Feb 2020 — May 2020 [monthly]
Active Not Recruiting PHASE3
-
Jan 2020 — Feb 2020 [monthly]
Active Not Recruiting PHASE3
-
Dec 2019 — Jan 2020 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Nov 2019 — Dec 2019 [monthly]
Recruiting PHASE3
-
Oct 2019 — Nov 2019 [monthly]
Recruiting PHASE3
Status: Active Not Recruiting → Recruiting
-
Aug 2019 — Oct 2019 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Jun 2019 — Aug 2019 [monthly]
Recruiting PHASE3
-
Apr 2019 — Jun 2019 [monthly]
Recruiting PHASE3
-
Mar 2019 — Apr 2019 [monthly]
Recruiting PHASE3
-
Feb 2019 — Mar 2019 [monthly]
Recruiting PHASE3
-
Jan 2019 — Feb 2019 [monthly]
Recruiting PHASE3
-
Nov 2018 — Jan 2019 [monthly]
Recruiting PHASE3
-
Sep 2018 — Nov 2018 [monthly]
Recruiting PHASE3
-
Aug 2018 — Sep 2018 [monthly]
Recruiting PHASE3
-
Jul 2018 — Aug 2018 [monthly]
Recruiting PHASE3
-
Jun 2018 — Jul 2018 [monthly]
Recruiting PHASE3
-
Jan 2018 — Jun 2018 [monthly]
Recruiting PHASE3
-
Dec 2017 — Jan 2018 [monthly]
Recruiting PHASE3
-
Oct 2017 — Dec 2017 [monthly]
Recruiting PHASE3
-
Aug 2017 — Oct 2017 [monthly]
Recruiting PHASE3
-
Jul 2017 — Aug 2017 [monthly]
Recruiting PHASE3
-
Jun 2017 — Jul 2017 [monthly]
Recruiting PHASE3
-
Apr 2017 — Jun 2017 [monthly]
Recruiting PHASE3
First recorded
Mar 2017
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Hoffmann-La Roche
For direct contact, visit the study record on ClinicalTrials.gov .